Fel d 1 and Fel d 4 levels in cat fur, saliva, and urine - 06/12/18
Doi : 10.1016/j.jaci.2018.07.033
Suzanne M. Kelly, PhD a 
, Jacob Karsh, MD, CM, FRCPC a, Jennifer Marcelo, BHSc a, Douglas Boeckh, DVM b, Nate Stepner, MHSc, D Litt a, Bryan Santone, HBSc, MBA a, Jimmy Yang, MBA a, William H. Yang, MD, FRCPC a
, Jacob Karsh, MD, CM, FRCPC a, Jennifer Marcelo, BHSc a, Douglas Boeckh, DVM b, Nate Stepner, MHSc, D Litt a, Bryan Santone, HBSc, MBA a, Jimmy Yang, MBA a, William H. Yang, MD, FRCPC a a Red Maple Trials, Ottawa, Ontario, Canada
b Merivale Cat Hospital, Ottawa, Ontario, Canada
| This research was funded by Red Maple Trials. |
|
| Disclosure of potential conflict of interest: S.M.K., J.K., B.S., J.Y., and W.H.Y. are principals of Red Maple Trials. J.M. and N.S. are employees of Red Maple Trials. D.B. is the veterinarian-owner of the Merivale Cat Hospital; he was reimbursed for his work in the study. |
© 2018
American Academy of Allergy, Asthma & Immunology. Publié par Elsevier Masson SAS. Tous droits réservés.
Vol 142 - N° 6
P. 1990 - décembre 2018 Retour au numéro
Article précédent
- Prophylactic and therapeutic inhibition of allergic airway inflammation by probiotic Escherichia coli O83
- Christian Zwicker, Priya Sarate, Mirjana Drini?, Katharina Ambroz, Elke Korb, Ursula Smole, Cordula Köhler, Mark S. Wilson, Hana Kozakova, Peter Sebo, Miloslav Kverka, Ursula Wiedermann, Irma Schabussova
- Personalized omalizumab treatment improves clinical benefit in patients with chronic spontaneous urticaria
- Tessa Niemeyer-van der Kolk, Maurits S. van Maaren, Martijn B.A. van Doorn
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?